Free Trial

Research Analysts Set Expectations for DRUG FY2025 Earnings

Bright Minds Biosciences logo with Medical background

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Equities researchers at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Bright Minds Biosciences in a report issued on Wednesday, July 2nd. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings of ($2.35) per share for the year, down from their previous forecast of ($0.64). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Bright Minds Biosciences' current full-year earnings is ($1.24) per share. Cantor Fitzgerald also issued estimates for Bright Minds Biosciences' FY2026 earnings at ($7.34) EPS.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.10.

A number of other equities analysts have also commented on the company. Wall Street Zen lowered Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Chardan Capital reiterated a "buy" rating and issued a $80.00 price objective on shares of Bright Minds Biosciences in a report on Wednesday, May 21st. TD Cowen started coverage on Bright Minds Biosciences in a report on Tuesday, May 13th. They issued a "buy" rating for the company. Finally, Cowen initiated coverage on Bright Minds Biosciences in a report on Tuesday, May 13th. They issued a "buy" rating for the company. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $83.25.

Get Our Latest Stock Analysis on DRUG

Bright Minds Biosciences Trading Down 3.1%

DRUG stock traded down $0.88 during trading on Friday, hitting $27.50. The company had a trading volume of 2,425 shares, compared to its average volume of 825,787. The company has a fifty day moving average price of $29.00 and a two-hundred day moving average price of $33.40. The company has a market cap of $193.56 million, a P/E ratio of -76.37 and a beta of -6.01. Bright Minds Biosciences has a fifty-two week low of $0.93 and a fifty-two week high of $79.02.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE acquired a new stake in Bright Minds Biosciences during the 4th quarter worth approximately $173,000. Jane Street Group LLC bought a new position in shares of Bright Minds Biosciences in the 4th quarter valued at $238,000. OMERS ADMINISTRATION Corp bought a new position in shares of Bright Minds Biosciences in the 1st quarter valued at $505,000. Atika Capital Management LLC acquired a new position in Bright Minds Biosciences in the 4th quarter worth about $540,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Bright Minds Biosciences in the first quarter valued at about $802,000. 40.52% of the stock is owned by institutional investors and hedge funds.

About Bright Minds Biosciences

(Get Free Report)

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.

Featured Articles

Earnings History and Estimates for Bright Minds Biosciences (NASDAQ:DRUG)

Should You Invest $1,000 in Bright Minds Biosciences Right Now?

Before you consider Bright Minds Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.

While Bright Minds Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines